Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now small index

Urothelial Carcinoma Ureter Recurrent clinical trials

1 of 1 indexed Urothelial Carcinoma Ureter Recurrent trials are currently recruiting.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Urothelial Carcinoma Ureter Recurrent: 1 US clinical trial tracked, 1 recruiting.

Urothelial Carcinoma Ureter Recurrent is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. The most active sponsor is UroGen Pharma, running 1 of these trials.

Enrollment posture brief

Registry condition urothelial-carcinoma-ureter-recurrent

OPEN 1 | RECR 100% | LATE 0 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Urothelial Carcinoma Ure (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Urothelial Carcinoma Ureter Recurrent

Urothelial Carcinoma Ureter Recurrent lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Urothelial Carcinoma Ureter Recurrent on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Urothelial Carcinoma Ureter Recurrent is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase Distribution

Phase data not available

Top Sponsors

UroGen Pharma 1 trials

Named interventions

Most-linked intervention names on Urothelial Carcinoma Ureter Recurrent records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Jelmyto (mitomycin) for pyelocalyceal solution Drug
1 trials

US sites by state

Facility locations filed on Urothelial Carcinoma Ureter Recurrent trials. A trial with sites in several states counts in each.

South Carolina 1 trials
Ohio 1 trials
New York 1 trials
New Jersey 1 trials
North Carolina 1 trials
Missouri 1 trials
Michigan 1 trials
Maryland 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Urothelial Carcinoma Ureter Recurrent page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Urothelial Carcinoma Ureter Recurrent trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • UroGen Pharma sponsors the most Urothelial Carcinoma Ureter Recurrent trials on record, review their full trial history before evaluating a specific study. See UroGen Pharma's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Urothelial Carcinoma Ureter Recurrent condition card totals 1 registered trials; most-linked intervention Jelmyto (mitomycin) for pyelocalyceal solution; top US site state South Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.